JAK3

JAK3

A gene on chromosome 19p13.1 that encodes a member of the Janus kinase (JAK) family of tyrosine kinases, which are involved in cytokine-receptor-mediated intracellular signal transduction. JAK3 is primarily expressed in immune cells and transduces a signal in response to activation via tyrosine phosphorylation by interleukin receptors.

Molecular pathology
JAK3 mutations are linked to autosomal severe combined immunodeficiency disease (SCID).
Mentioned in ?
References in periodicals archive ?
JAK3 is a validated target in atopic dermatitis, psoriasis and pruritus.
Sienna Biopharmaceuticals doses first patient in SNA-125 Phase 1/2 trial
The interaction between IL-21 and its receptor can induce activation of Janus kinase (JAK)-1 and JAK3 and then activate signal transducers and activators of transcription (STAT) 1 and STAT3.
Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis
There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.
Lilly to File Baricitinib Resubmission to US FDA before end of January 2018
According to the companies, Baricitinib is a once-daily oral JAK inhibitor and are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.
Lilly & Incyte partnership to file Baricitinib Resubmission for the treatment of rheumatoid arthritis with US FDA
JAK family kinases including JAK1, JAK2, Tyk2, and JAK3 play vital roles in homeostasis and immune responses.
RHEUMATOID ARTHRITIS THERAPIES: PRESENT AND FUTURE
1,3) These include EGFR, HER2, HER4, ITK, BMX, JAK3, TEC, and BLK.
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia
This laboratory-developed NGS test protocol is based on a well-validated research use-only kit that targets 54 genes, including all exons of 15 genes (BCOR, BCORL1, CDKN2A, CEBPA, CUX1, DNMT3A, ETV6, EZH2, IKZF1, KDM6A, PHF6, RAD21, RUNX1, STAG2, and ZRSR2) and hot spot exons/regions of 39 genes (ABL1, ASXL1, ATRX, BRAF, CALR, CBL, CBLB, CBLC, CSF3R, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, JAK2, JAK3, KIT, KMT2A/MLL, KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PTEN, PTPN11, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, TET2, TP53, U2AF1, and WT1).
Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms
EGFR mutations, anaplastic lymphoma kinase (ALK) fusions, and proto-oncogene tyro sine-protein kinase (ROS1) were detected in non-smokers and smokers, while tumor protein p53 (TP53), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), proto-oncogene B-Raf (BRAF), Janus kinase 2 (JAK2), JAK3, and mismatch repair gene mutations were detected in smokers.
Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation
An oral Janus kinase (JAK) inhibitor, tofacitinib blocks JAK1, JAK3, and to a lesser extent JAK2.
Small molecules for psoriasis
Phosphorylation of EZH2 by JAK3 leads to dissociation of EZH2 from PRC2 complex, leading to a non-catalytic activity of EZH2 to promote cancer cell proliferation.
Singapore : Singapore scientists discover new pathways leading to cancer progression
Blood, under the title, "EZH2 phosphorylation by JAK3 mediates a switch to non-canonical function in natural killer/T-cell lymphoma" by Junli Yan 1, Boheng Li 2, Baohong Lin 3, Pei Tsung Lee 1, Tae-Hoon Chung 1, Joy Tan 1, Chonglei Bi 1, Xue Ting Lee 1, Viknesvaran Selvarajan 4, Siok-Bian Ng 1,2,4, Henry Yang 1, Qiang Yu 5, Wee-Joo Chng 1,2,3
Singapore Scientists Discover New Pathways Leading to Cancer Progression
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: role in apoptosis induction and radiosensitization in head and neck tumor cells

Medical browser ?
Full browser ?